Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD - 19/04/17
Doi : 10.1016/j.jaci.2016.08.028
Alina E. Dulau Florea, MD a, Raul C. Braylan, MD a, Kristian T. Schafernak, MD, MPH b, c, Kelli W. Williams, MD, MPH d, Janine Daub, MSN d, Rakesh K. Goyal, MD e, Jennifer M. Puck, MD f, V. Koneti Rao, MD d, Stefania Pittaluga, MD, PhD g, Steven M. Holland, MD d, Gulbu Uzel, MD d, Katherine R. Calvo, MD, PhD a 
a Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md
b Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill
c Division of Pathology and Laboratory Medicine, Phoenix Children's Hospital, Phoenix, Ariz
d Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
e Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa
f Department of Pediatrics, University of California San Francisco, San Francisco, Calif
g Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md
| This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Cancer Institute, and National Institutes of Health Clinical Center. The content of this letter does not necessarily reflect the views or policies of the Department of Health and Human Services. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflict of interest. |
© 2016
Publié par Elsevier Masson SAS.
Vol 139 - N° 3
P. 1032 - mars 2017 Retour au numéro
Article précédent
- Are dust mite allergens more abundant and/or more stable than other Dermatophagoides pteronyssinus proteins?
- Ryenne N. Ogburn, Thomas A. Randall, Yingrong Xu, Julia H. Roberts, Betelihem Mebrahtu, Jaret M. Karnuta, S. Dean Rider, Grace E. Kissling, Robert E. London, Anna Pomés, Larry Arlian, Michael C. Fitzgerald, Geoffrey A. Mueller
- Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site
- Karin A. van Schie, Simone Kruithof, Pauline A. van Schouwenburg, Anke Vennegoor, Joep Killestein, Gertjan Wolbink, Theo Rispens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?